الفهرس Only 14 pages are availabe for public view
 |  | from | 256 |  |  |
| | | from | 256 | | |
Abstract
NHL comprises an extremely heterogeneous group of clonal LPDs that might be derived from either B-cell or T/NK-cell lineages. Within this broad term of NHL, numerous disease entities with variable clinical behavior and diverse molecular features were included.
The identification of genes involved in the pathogenesis of NHL has yielded a practical benefit of allowing the development of highly specific and sensitive cytogenetic and molecular assays. These assays have greatly improved lymphoma diagnosis through resolving diagnostic ambiguities brought about by the more traditional classification methods; which were subsequently refined following the identification of non-random chromosomal aberrations specific to each lymphoma subtype.
Moreover, cytogenetic and molecular assays have allowed patients’ follow up aiming for detection of minimal residual disease (MRD), prediction of patients’ outcome, in addition to providing the rationale for designing novel molecular-targeted therapeutic strategies, specific for genetically altered lymphoma cells and hence devoid of the major side effects encountered with antineoplastic therapy.